|
MechanismMitochondrial complex I: NADH:ubiquinone oxidoreductase subunits inhibitors [+1] |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
A Single-Blind, Placebo-Controlled, Randomized First Time in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Dose Escalation of GSK932121 in Healthy Adult Subjects
The purpose of this study is to determine if the study drug (antimalarial medication) is safe when given to healthy subjects as a single dose or as repeated doses, to understand the effect of food on single doses of study drug and to determine if the study drug has an effect on other approved medications such as rosiglitazone and rosuvastatin.
100 Clinical Results associated with Mitochondrial complex I (NADH dehydrogenase) x Pfbc1
100 Translational Medicine associated with Mitochondrial complex I (NADH dehydrogenase) x Pfbc1
0 Patents (Medical) associated with Mitochondrial complex I (NADH dehydrogenase) x Pfbc1